- WKN: 121806
- ISIN: DE0001218063
- Land: Deutschland
Nachricht vom 10.05.2021 | 10:00
FinLab AG: AUTHADA is launching a secure electronic signature solution on the market. AUTHADA now offers QES and identification from a single source
Frankfurt and Darmstadt, Germany / Rome, Italy, May 10th, 2021 - The certified identification service provider AUTHADA GmbH, a portfolio company of Frankfurt-based FinLab AG (ISIN: DE0001218063; Ticker: A7A.GR) is expanding its product portfolio and today is launching - together with InfoCert, Europe's largest certification authority -a secure electronic signature solution on the market: With sign, users can sign and exchange documents electronically in compliance with the law. For this purpose, sign provides the so-called "Qualified Electronic Signature" (QES): As a signature procedure with the highest level of assurance, the QES is equivalent to a handwritten signature according to the European eIDAS regulation ("electronic Identification, Authentication and Trust Services").
Companies in trade, the financial or real estate sector and many other industries can efficiently digitalise their contract processes. Not only does sign drastically reduce the time it takes to execute a contract, as well as the associated costs and efforts: the digitalisation of the contract process also ensures enormous scalability. Opening and office hours no longer play a role in the digital world, contracts can now be executed 24/7.
Perfectly integrated solution
Robin Acker, CPO and co-founder of AUTHADA: "The new QES solution sign is a perfect addition to our app-based identification solution AUTHADA ident, which allows identification using the electronic ID card. Both solutions are quick and easy to integrate, can be ideally combined and offer our customers a future-oriented complete package in terms of secure process efficiency."
AUTHADA with the highest possible level of assurance
To make this possible, the European legislator specifies in the eIDAS Regulation exactly how the QES is to be implemented technically. AUTHADA and InfoCert implement all these regulatory and legal requirements together: AUTHADA contributes its concentrated digital identification expertise in the form of app-based eID identification, whereas InfoCert is responsible for generating the valid qualified certificate. This is because a QES is based on a qualified certificate that is valid at the time of its generation and is created with a secure signature creation device. AUTHADA's signature procedures represent a very secure and efficient process through the combination of eID identification and QES. "Covid catapulted our society into a world characterised by digital interactions. Some interactions need to be managed at a higher level of assurance because of their critical and/or sensitive nature. That's where digital signatures are required. With millions of digital signatures managed on a daily basis, InfoCert is the largest Certification Authority in Europe and we are extremely proud of our strategic partnership with AUTHADA. By combining the unique propositions of the two companies we are able to offer German citizens the possibility to use their identity card to digitally sign any kind of document at the highest legal value." stated Carmine Auletta, InfoCert Chief Innovation and Strategy Officer.
About FinLab AG:
End of Media Release
Issuer: FinLab AG
Key word(s): Research/Technology
|Phone:||+49 (0)69 719 12 80 - 0|
|Fax:||+49 (0)69 719 12 80 - 011|
|Listed:||Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Scale), Stuttgart, Tradegate Exchange|
|EQS News ID:||1194256|
|End of News||DGAP Media|
FinLab AG: Half-year results as of 30/06/2021
FinLab AG: Termination of Matthias Kröner's ma ...
FinLab AG: FinLab transfers asset management m ...
FinLab AG: FinLab investment Deposit Solutions ...
FinLab AG: AUTHADA is launching a secure elect ...
GBC im Fokus
IGEA Pharma N.V. Realignment to CBD extraction
The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.
Der AKTIONÄR News
26. November 15:53 Devisen: Droht wegen Lira-Crash eine Banken-Krise?
26. November 15:59 Performance mit Megatrendaktien
26. November 16:00 Gigantisch: 100 Millionen Roboter für Nvidia und Meta sorgen für ...
26. November 16:04 Zoom: Richtungswechsel, aber Chartbild bleibt eindeutig
26. November 16:15 Sartorius: 70 Prozent Trading-Chance bei diesem Corona-Profiteur
News im Fokus
Infineon Technologies AG: Aufsichtsrat beruft Jochen Hanebeck zum Nachfolger von Dr. Reinhard Ploss als Vorstandsvorsitzenden von Infineon
25. November 2021, 17:45
Original-Research: 3U HOLDING AG (von GSC Research GmbH): Halten
26. November 2021